Concr

Concr is a deeptech and techbio company based in London, England, with a subsidiary in Brisbane, Australia. The company specializes in predictive analytics and artificial intelligence (AI) to enhance precision medicine and improve cancer drug development. Concr's solutions focus on accurately predicting patient and cohort responses to cancer treatments, which supports more effective clinical trials and early-stage development. The company's flagship product, the Farr-Sight® platform, utilizes advanced modeling techniques derived from astrophysics research to simulate human disease biology. This cloud-based tool enables personalized treatment approaches and improves trial outcomes by integrating genomic knowledge and advanced analytics. Concr collaborates with various partners, including Roche and The Institute of Cancer Research, to validate its technology and enhance research and clinical applications in oncology.